These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 24729718)

  • 61. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.
    Abdelnour A; Silas PE; Lamas MR; Aragón CF; Chiu NC; Chiu CH; Acuña TH; Castrejón Tde L; Izu A; Odrljin T; Smolenov I; Hohenboken M; Dull PM
    Vaccine; 2014 Feb; 32(8):965-72. PubMed ID: 24397906
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
    Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
    Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old children.
    Vesikari T; Forsten A; Laudat F; Li P; Van Der Wielen M; Hezareh M; Perez JL; Webber C
    Vaccine; 2020 May; 38(22):3902-3908. PubMed ID: 32284274
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults: An Open, Randomized Trial.
    Baxter R; Baine Y; Kolhe D; Baccarini CI; Miller JM; Van der Wielen M
    Pediatr Infect Dis J; 2015 Nov; 34(11):1236-43. PubMed ID: 26237742
    [TBL] [Abstract][Full Text] [Related]  

  • 65. One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children.
    Klein NP; Baine Y; Bianco V; Lestrate PR; Naz A; Blatter M; Friedland LR; Miller JM
    Pediatr Infect Dis J; 2013 Jul; 32(7):760-7. PubMed ID: 23348814
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Antibody persistence and booster response 68 months after vaccination at 2-10 years of age with one dose of MenACWY-TT conjugate vaccine.
    Knuf M; Helm K; Kolhe D; Van Der Wielen M; Baine Y
    Vaccine; 2018 May; 36(23):3286-3295. PubMed ID: 29724511
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT).
    Østergaard L; Van der Wielen M; Bianco V; Miller JM
    Int J Infect Dis; 2013 Mar; 17(3):e173-6. PubMed ID: 23246368
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antibody persistence following meningococcal ACWY conjugate vaccine licensed in the European Union by age group and vaccine.
    Luo W; Arkwright PD; Borrow R
    Expert Rev Vaccines; 2020 Aug; 19(8):745-754. PubMed ID: 32897762
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Meningococcal vaccine A,C,W135,Y: conjugated to tetanus toxoid.
    Prescrire Int; 2013 Dec; 22(144):285-8. PubMed ID: 24600724
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates.
    Kimura A; Toneatto D; Kleinschmidt A; Wang H; Dull P
    Clin Vaccine Immunol; 2011 Mar; 18(3):483-6. PubMed ID: 21177912
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age.
    Ishola DA; Andrews N; Waight P; Yung CF; Southern J; Bai X; Findlow H; Matheson M; England A; Hallis B; Findlow J; Borrow R; Miller E
    Pediatr Infect Dis J; 2015 Aug; 34(8):865-74. PubMed ID: 26075813
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
    Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
    Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Preclinical development of the quadrivalent meningococcal (ACYW) tetanus toxoid conjugate vaccine, MenQuadfi®.
    Kensinger R; Arunachalam AB
    Glycoconj J; 2022 Jun; 39(3):381-392. PubMed ID: 35441968
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix™): A review of its immunogenicity, safety, co-administration, and antibody persistence.
    Assaf-Casals A; Dbaibo G
    Hum Vaccin Immunother; 2016 Jul; 12(7):1825-37. PubMed ID: 26900984
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children.
    Knuf M; Baine Y; Bianco V; Boutriau D; Miller JM
    Hum Vaccin Immunother; 2012 Jul; 8(7):866-72. PubMed ID: 22485049
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years.
    Ostergaard L; Lebacq E; Poolman J; Maechler G; Boutriau D
    Vaccine; 2009 Jan; 27(1):161-8. PubMed ID: 18834910
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT.
    Findlow H; Borrow R
    Adv Ther; 2013 May; 30(5):431-58. PubMed ID: 23712402
    [TBL] [Abstract][Full Text] [Related]  

  • 79. An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine.
    Keshavan P; Pellegrini M; Vadivelu-Pechai K; Nissen M
    Expert Rev Vaccines; 2018 Oct; 17(10):865-880. PubMed ID: 30198805
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and Safety of Quadrivalent Conjugate Meningococcal Vaccines: A Systematic Review and Meta-Analysis.
    Conti A; Broglia G; Sacchi C; Risi F; Barone-Adesi F; Panella M
    Vaccines (Basel); 2023 Jan; 11(1):. PubMed ID: 36680022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.